Table 3.

The impact of hypothyroidism and the TSH level on overall survival and recurrence‐free survival adjusted for different covariates

	Hypothyroidism		Hypothyroidism‐2		TSH
	AHR	P	AHR	P	AHR	P
OS‐model1	1.78 (1.01, 3.13)	0.047	1.86 (1.15, 3.02)	0.012	1.05 (1.02, 1.08)	0.0006
OS‐model2	1.96 (1.10, 3.49)	0.022	2.05 (1.25, 3.35)	0.004	1.06 (1.03, 1.09)	0.0003
OS‐model3	2.25 (1.18, 4.28)	0.014	2.45 (1.44, 4.18)	0.0009	1.05 (1.02, 1.09)	0.0026
RFS‐model1	2.43 (1.10, 5.35)	0.027	1.93 (0.94, 3.96)	0.073	1.09 (1.04, 1.13)	0.0001
RFS‐model2	3.03 (1.35, 6.77)	0.007	2.23 (1.07, 4.63)	0.033	1.09 (1.05, 1.14)	<0.0001
RFS‐model3	5.54 (2.36, 13.01)	0.0001	3.01 (1.36, 6.64)	0.006	1.08 (1.03, 1.13)	0.0030

OS‐model1 adjusted for age, gender, race/ethnicity; OS‐model2 adjusted for smoking, obesity, diabetes, and hypertension in addition to OS‐model1; and OS‐model3 adjusted for cirrhosis, neutrophil to lymphocyte ratio (NLR), alpha‐fetoprotein (AFP), model for end‐stage liver disease (MELD) score, tumor diameter, vascular invasion, and Milan criteria in addition to OS‐model2. RFS‐model1 adjusted for age, gender, race/ethnicity; RFS‐model2 adjusted for smoking, obesity, diabetes, and hypertension in addition to RFS‐model1; and RFS‐model3 adjusted for autoimmune liver disease (AILD), Child‐Turcotte‐Pugh (CTP) score, tumor diameter, vascular invasion, and Milan criteria in addition to RFS‐model2.

AHR, adjusted hazard ratio; OS, overall survival; RFS, recurrence‐free survival; TSH, thyroid‐stimulating hormone.